Methods of using and compositions containing dulaglutide
AssigneeEli Lilly and Company
InventorsDavid Andrew Cox, Zvonko Milicevic, Lai San Tham, Andrew Gordon Werner, David Bradley Woodward
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of using new doses of dulaglutide and compositions containing such higher doses of dulaglutide
Claims17
-35. (canceled)
A method of improving glycemic control in a subject in need thereof with type 2 diabetes comprising administering dulaglutide to the subject, wherein the administering comprises
- a) a starting dose of 0.75 mg of dulaglutide administered once weekly:
- b) increasing the dose to 1.5 mg of dulaglutide administered once weekly for at least 4 weeks:
- and
- c) further increasing the once weekly administered dulaglutide dose to a dose of 3.0 mg.
A method of improving glycemic control in a subject in need thereof with type 2 diabetes comprising administering dulaglutide by injection to the subject, wherein the administering comprises
- a) a starting dose of 0.75 mg of dulaglutide administered once weekly:
- b) increasing the dose to 1.5 mg of dulaglutide administered once weekly for at least 4 weeks:
- and
- c) further increasing the once weekly administered dulaglutide dose by 1.5 mg increments after at least 4 weeks of administering a prior dose, up to a maximum dose of 4.5 mg.
A method of improving glycemic control in a subject in need thereof with type 2 diabetes comprising administering to the subject a 3.0 mg dose of dulaglutide once weekly by injection.
A method of improving glycemic control in a subject in need thereof with type 2 diabetes comprising administering to the subject a 4.5 mg dose of dulaglutide once weekly by injection.
Dependencies are inferred from the claim text.